Ultragenyx Pharmaceutical | RARE - Despesas Operacionais

Preço das Ações
19.87
Mudança Diária
-0.55 -2.69%
Mensal
-11.73%
Anual
-49.29%
Q1 Previsão
19.27




Despesas Operacionais Alterar Data
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Immunic USD 25.73M 2.91M 2024-09
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Kyowa Hakko Kirin JPY 109.02B 16.08B 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xoma USD 22.84M 1.67M 2024-09